I
Ionis Pharmaceuticals, Inc. (IONS)
NMS – Real Time Price. Currency in USD
75.83
+0.45 (0.60%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
75.83
+0.45 (0.60%)
At close: May 12, 2026, 4:00 PM EDT
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
| Name | Position |
|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, CEO & Director |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive VP & Chief Scientific Officer |
| Dr. Eric E. Swayze Ph.D. | Executive Vice President of Research |
| Dr. Eugene Schneider M.D. | Executive VP, Chief Clinical Development & Operations Officer |
| Dr. Richard S. Geary Ph.D. | Strategic Consultant |
| Mr. Brian Birchler | Executive Vice President of Corporate & Development Operations |
| Mr. D. Wade Walke Ph.D. | Senior Vice President of Investor Relations |
| Mr. Darren Gonzales | Chief Accounting Officer & Senior VP |
| Mr. Patrick R. O'Neil Esq. | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary |
| Ms. Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive VP of Finance & CFO |
| Date | Type | Document |
|---|---|---|
| 2026-04-29 | 8-K | ef20071749_8k.htm |
| 2026-04-29 | 10-Q | form10q.htm |
| 2026-04-23 | DEFA14A | ny20063671x2_defa14a.htm |
| 2026-04-23 | ARS | ny20063671x3_ars.pdf |
| 2026-04-21 | 8-K | ef20071051_8k.htm |
| 2026-03-09 | 8-K | ef20067398_8k.htm |
| 2026-02-26 | 10-K | form10k.htm |
| 2026-02-25 | 8-K | ef20066495_8k.htm |
| 2026-01-12 | 8-K | ef20062670_8k.htm |
| 2026-01-07 | 8-K | ef20062477_8k.htm |